LAVA Therapeutics N.V.
NASDAQ Global SelectTotal Valuation
LAVA Therapeutics N.V. carries a market capitalization of 45.77M, placing it among publicly traded companies globally. Its enterprise value stands at -7.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 45.77M |
| Enterprise Value | -7.72M |
Share Statistics
LAVA Therapeutics N.V. currently has 26.31M shares outstanding.
| Shares Outstanding | 26.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8.41, and the price-to-book ratio stands at -0.22.
| PE Ratio | N/A |
| PS Ratio | 8.41 |
| PB Ratio | -0.22 |
| P/TBV Ratio | 3.31 |
| P/FCF Ratio | -1.32 |
| P/OCF Ratio | -1.32 |
Financial Position
LAVA Therapeutics N.V. maintains a current ratio of 12.27, meaning it holds 12.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.27 |
| Quick Ratio | 11.74 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -229.67 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -34.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 683,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
LAVA Therapeutics N.V.'s stock has gained approximately 75.75758% over the past 52 weeks. The 50-day moving average sits at 1.59, while the 200-day moving average is 1.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 75.75758% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, LAVA Therapeutics N.V. generated 4.99M in revenue and converted that into -23.28M in net income, yielding earnings per share of -0.87. EBITDA reached -29.63M, while operating income came in at -29.53M.
| Revenue | 4.99M |
| Gross Profit | 4.99M |
| Operating Income | -29.53M |
| Pretax Income | -22.59M |
| Net Income | -23.28M |
| EBITDA | -29.63M |
| EBIT | -29.53M |
| Earnings Per Share (EPS) | -0.87 |
Balance Sheet
Total book value stands at -190.56M, with working capital of 47.67M providing operational flexibility.
| Cash & Cash Equivalents | 49.66M |
| Total Debt | N/A |
| Net Debt | -49.66M |
| Equity (Book Value) | -190.56M |
| Book Value Per Share | -7.09 |
| Working Capital | 47.67M |
Cash Flow
LAVA Therapeutics N.V. produced -31.67M in operating cash flow over the past twelve months.
| Operating Cash Flow | -31.67M |
| Capital Expenditures | N/A |
| Free Cash Flow | -31.67M |
| FCF Per Share | -1.18 |
Margins
LAVA Therapeutics N.V. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -591.70 and net profit margin of -466.45 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -591.70 |
| Pretax Margin | -452.77 |
| Profit Margin | -466.45 |
| EBITDA Margin | -593.75 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.49 |
| FCF Yield | -75.49 |
Scores
LAVA Therapeutics N.V. posts an Altman Z-Score of -5.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.28 |